作者：
Christian,J.B. [1]
;
Finkle,J.K. [2]
;
Ky,B. [3]
;
Douglas,P.S. [4]
;
Gutstein,D.E. [5]
;
Hockings,P.D. [6]
;
Lainee,P. [7]
;
Lenihan,D.J. [8]
;
Mason,J.W. [9]
;
Sager,P.T. [10]
;
Todaro,T.G. [11]
;
Hicks,K.A. [12]
;
Kane,R.C. [13]
;
Ko,H.-S. [14]
;
Lindenfeld,J. [15]
;
Michelson,E.L. [16]
;
Milligan,J. [17]
;
Munley,J.Y. [18]
;
Raichlen,J.S. [19]
;
Shahlaee,A. [20]
;
Strnadova,C. ;
Ye,B. ;
Turner,J.R.
作者单位：
Medpace, Cincinnati, OH, United States
[1]
University of Utah, Salt Lake City, UT, United States
[2]
AstraZeneca LP, Wilmington, DE, United States
[3]
FDA, Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Silver
[4]
Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN, United States
[5]
Quintiles, Durham, NC, United States
[6]
Sager Consulting Partners, San Francisco, CA, United States
[7]
FDA, Division of Medical Imaging Products, Center for Drug Evaluation and Research, Silver Spring
[8]
GlaxoSmithKline, Upper Providence, PA, United States
[9]
Division of Cardiovascular Medicine, University of Pennsylvania School of Medicine, Philadelphia
[10]
AstraZeneca AB, M?lndal, Sweden
[11]
FDA, Division of Hematology Products, Center for Drug Evaluation and Research, Silver Spring, MD
[12]
FDA, Division of Dermatology and Dental Products, Center for Drug Evaluation and Research, Silver
[13]
Health Canada, Ottawa, Canada
[14]
FDA, Office of Hematology and Oncology Products, Silver Spring, MD, United States
[15]
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, United States
[16]
Department of Medicine, University of Colorado, Aurora, CO, United States
[17]
AstraZeneca, Cheshire, United Kingdom
[18]
Clinical Effectiveness and Safety, GlaxoSmithKline, 5 Moore Drive, B.3116, Durham, NC 27709, United
[19]
Merck Sharp and Dohme Corp., Rahway, NJ, United States
[20]
发布时间
2013-11-20
换一批
